Patents by Inventor Samir Cherkaoui
Samir Cherkaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905323Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: GrantFiled: May 18, 2022Date of Patent: February 20, 2024Assignee: Bracco SuisseInventors: Federico Maisano, Federico Crivellin, Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Christian Koller, Adrian Lobito
-
Publication number: 20230404920Abstract: The present invention relates to calibrated (per)fluorocarbon nanodroplets comprising an outer layer and an inner core, said outer layer comprising a biocompatible fluorinated surfactant and said inner core comprising a (per)fluorocarbon. The invention further relates to a method of preparation of said calibrated (per)fluorocarbon nanodroplets through microfluidic technique, and to their use for in vivo or in vitro diagnostic and/or for therapy.Type: ApplicationFiled: November 11, 2021Publication date: December 21, 2023Inventors: Romain MELICH, Philippe BUSSAT, Samir CHERKAOUI, Christiane CONTINO-PEPIN, Stéphane DESGRANGES
-
Patent number: 11717570Abstract: Lipid formulation particularly for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio. The formulation is useful in particular for therapeutic application with ultrasounds.Type: GrantFiled: May 14, 2020Date of Patent: August 8, 2023Assignee: Bracco Suisse SAInventors: Philippe Bussat, Samir Cherkaoui, David Lazarus, Eric Allémann, Michel Schneider, Christian Guillot
-
Publication number: 20220409749Abstract: The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic material and a mixture of freeze-drying protecting components, which may be reconstituted for preparing a suspension of gas-filled microvesicles with calibrated size, useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.Type: ApplicationFiled: June 24, 2020Publication date: December 29, 2022Applicant: Bracco Suisse SAInventors: Anne LASSUS, Samir CHERKAOUI
-
Publication number: 20220389080Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: ApplicationFiled: May 18, 2022Publication date: December 8, 2022Applicant: Bracco Suisse SAInventors: Federico MAISANO, Federico CRIVELLIN, Thierry BETTINGER, Philippe BUSSAT, Samir CHERKAOUI, Christian KOLLER, Adrian LOBITO
-
Publication number: 20220339301Abstract: The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic material and a freeze-drying protecting component, which may be reconstituted for preparing a suspension of gas-filled microvesicles with calibrated size, useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.Type: ApplicationFiled: June 24, 2020Publication date: October 27, 2022Applicant: Bracco Suisse SAInventors: Anne LASSUS, Samir CHERKAOUI
-
Publication number: 20220211850Abstract: Lipid formulation particularly for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio. The formulation is useful in particular for therapeutic application with ultrasounds.Type: ApplicationFiled: May 14, 2020Publication date: July 7, 2022Applicant: Bracco Suisse SAInventors: Philippe Bussat, Samir CHERKAOUI, David LAZARUS, Eric ALLÉMANN, Michel SCHNEIDER, Christian GUILLOT
-
Patent number: 11370826Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: GrantFiled: February 9, 2017Date of Patent: June 28, 2022Assignee: Bracco Suisse SAInventors: Federico Maisano, Federico Crivellin, Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Christian Koller, Adrian Lobito
-
Publication number: 20210389320Abstract: Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.Type: ApplicationFiled: December 19, 2019Publication date: December 16, 2021Applicant: Bracco Suisse SAInventors: Philippe BUSSAT, Samir CHERKAOUI, David LAZARUS
-
Patent number: 10918605Abstract: A method for preparing a suspension of size-controlled microparticles stabilized by a layer of amphiphilic material. The method, which may be applied to preparations using microfluidic techniques, comprises controlling the temperature of the microparticles during the preparation process and preferably while collecting the formed microparticles.Type: GrantFiled: August 30, 2017Date of Patent: February 16, 2021Assignee: Bracco Suisse SAInventors: Tim Segers, Peter Frinking, Anne Lassus, Philippe Bussat, Emmanuel Gaud, Samir Cherkaoui
-
Publication number: 20190175516Abstract: A method for preparing a suspension of size-controlled microparticles stabilized by a layer of amphiphilic material. The method, which may be applied to preparations using microfluidic techniques, comprises controlling the temperature of the microparticles during the preparation process and preferably while collecting the formed microparticles.Type: ApplicationFiled: August 30, 2017Publication date: June 13, 2019Applicant: Bracco Suisse SAInventors: Tim SEGERS, Peter FRINKING, Anne LASSUS, Philippe BUSSAT, Emmanuel GAUD, Samir CHERKAOUI
-
Publication number: 20190048062Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: ApplicationFiled: February 9, 2017Publication date: February 14, 2019Applicant: Bracco Suisse SAInventors: Federico MAISANO, Federico CRIVELLIN, Thierry BETTINGER, Philippe BUSSAT, Samir CHERKAOUI, Christian KOLLER, Adrian LOBITO
-
Publication number: 20160263254Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: June 1, 2016Publication date: September 15, 2016Inventors: Philippe BUSSAT, Samir Cherkaoui, Hong Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 9381258Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: July 23, 2013Date of Patent: July 5, 2016Assignee: Bracco Suisse S.A.Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 9333273Abstract: Gas-filled microvesicles associated with a polypeptide comprising a sequence of amino acids, said sequence exhibiting binding affinity for selectins, particularly p-selectin. The gas-filled microvesicles can be used in ultrasound imaging.Type: GrantFiled: October 30, 2015Date of Patent: May 10, 2016Assignee: BRACCO SUISSE S.A.Inventors: Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Irene Guilbert-Brigger, Bernard Lamy
-
Patent number: 9295737Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: February 26, 2014Date of Patent: March 29, 2016Assignee: BRACCO SUISSE SAInventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20160074539Abstract: Gas-filled microvesicles associated with a polypeptide comprising a sequence of amino acids, said sequence exhibiting binding affinity for selectins, particularly p-selectin. The gas-filled microvesicles can be used in ultrasound imaging.Type: ApplicationFiled: October 30, 2015Publication date: March 17, 2016Applicant: BRACCO SUISSE S.A.Inventors: Thierry BETTINGER, Philippe BUSSAT, Samir CHERKAOUI, Irene GUILBERT-BRIGGER, Bernard LAMY
-
Patent number: 9211348Abstract: Gas-filled microvesicles associated with a polypeptide comprising a sequence of amino acids, said sequence exhibiting binding affinity for selectins, particularly p-selectin. The gas-filled microvesicles can be used in ultrasound imaging.Type: GrantFiled: August 9, 2011Date of Patent: December 15, 2015Assignee: BRACCO SUISSE S.A.Inventors: Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Irene Guilbert-Brigger, Bernard Lamy
-
Publication number: 20140206837Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: February 26, 2014Publication date: July 24, 2014Applicant: BRACCO SUISSE SAInventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20140031520Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: July 23, 2013Publication date: January 30, 2014Applicant: Bracco Suisse SAInventors: Philippe BUSSAT, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson